DNAnexus, Inc. Secures $15 Million in Financing, Led by Google Ventures

DNAnexus recently announced it has closed a $15-million Series C funding led by Claremont Creek Ventures, Google Ventures, TPG Biotech, and First Round Capital. The company’s innovative Platform-as-a-Service (PaaS), is experiencing rapid customer adoption and delivers a cost-effective solution to the challenges that global enterprises face when building clinically compliant analysis pipelines for DNA sequence data.

DNAnexus was designed to accelerate basic science and clinical breakthroughs by providing a centralized hub for managing data, collaborating with other scientists, sharing tools, and accessing diverse reference datasets, including genotypic and phenotypic data. The platform provides labs of any size a secure and compliant cloud platform that supports the unlimited scaling of computational and storage resources. Through DNAnexus, global collaborators can connect effortlessly, while remaining compliant with HIPAA, CLIA, and international regulatory requirements.

“This is an exciting time of growth for DNAnexus,” said Richard Daly, CEO of DNAnexus. “This funding will significantly expand our capacity to support the growing number of commercial and academic labs around the world utilizing our platform to manage DNA data and analyses in a clinically appropriate manner. We welcome Claremont Creek Ventures to the team and are pleased with the continued support from Google Ventures, TPG Biotech, and First Round Capital.”

Recently, DNAnexus announced large-scale projects with Stanford University and Baylor College of Medicine that demonstrate the value of the company’s platform in processing tens of thousands of genomes and making the resulting data sets securely available to researchers around the world. Through these two projects alone, DNAnexus processed over 17,000 genomes and generated more than 500 terabytes of genomic data. The resulting data sets can be accessed on DNAnexus and are available for follow-on analysis and data sharing to researchers participating in the 1000 Genomes Project and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium.

“We are thrilled to support an important computational tool that will accelerate the critical transition from pure research to ubiquitous clinical application,” added Nat Goldhaber, Managing Director at Claremont Creek Ventures and new DNAnexus Board Member.

“The next wave of insights in genetics comes from multi-institutional collaborative efforts producing huge amounts of data. DNAnexus has created a system where large enterprises, laboratories, and individuals can collaborate more efficiently using modern cloud technologies,” said Krishna Yeshwant, Google Ventures General Partner and DNAnexus Board Member. “DNAnexus is changing how global biomedical research and development markets manage DNA data and analytic infrastructures.”

DNAnexus is powering the genomics revolution with an enterprise-level solution that combines cloud computing with advanced bioinformatics. The DNAnexus team is made up of experts in software, computational biology, and genetics who are on a mission to establish DNAnexus at the center of a growing ecosystem of scientific and clinical research, and diagnostic efforts in personalized medicine. For more information visit www.dnanexus.com.